News
OMGA
2.330
-0.43%
-0.010
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
NASDAQ · 2d ago
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
NASDAQ · 2d ago
Weekly Report: what happened at OMGA last week (0415-0419)?
Weekly Report · 2d ago
CVAC, SBNY and CRMD are among after hour movers
Seeking Alpha · 04/17 21:01
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
NASDAQ · 04/17 13:55
Omega Therapeutics CFO Joshua Reed to depart
Seeking Alpha · 04/16 20:47
OMEGA THERAPEUTICS INC - DESIGNATED BARBARA CHAN AS ITS PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER
Reuters · 04/16 20:21
Weekly Report: what happened at OMGA last week (0408-0412)?
Weekly Report · 04/15 09:13
Omega Therapeutics Presents New Preclinical Data Supporting The Potential Of Precision Epigenomic Control At AACR 2024
Benzinga · 04/09 11:06
Weekly Report: what happened at OMGA last week (0401-0405)?
Weekly Report · 04/08 09:14
Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know
NASDAQ · 04/03 16:00
Omega Therapeutics Price Target Cut to $9.00/Share From $10.00 by Piper Sandler
Dow Jones · 04/03 15:38
Piper Sandler Reiterates Overweight on Omega Therapeutics, Lowers Price Target to $9
Benzinga · 04/03 15:27
Omega Therapeutics (OMGA) Receives a Buy from Piper Sandler
TipRanks · 04/03 11:06
OMEGA THERAPEUTICS INC <OMGA.O>: PIPER SANDLER CUTS TARGET PRICE TO $9 FROM $10
Reuters · 04/03 03:01
Omega Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 04/01 12:34
Omega Therapeutics Price Target Cut to $7.00/Share From $12.00 by Chardan Capital
Dow Jones · 04/01 12:34
Chardan Capital Maintains Buy on Omega Therapeutics, Lowers Price Target to $7
Benzinga · 04/01 12:24
Weekly Report: what happened at OMGA last week (0325-0329)?
Weekly Report · 04/01 09:14
OMEGA THERAPEUTICS INC <OMGA.O>: CHARDAN CAPITAL MARKETS CUTS TARGET PRICE TO $7 FROM $12
Reuters · 04/01 04:23
More
Webull provides a variety of real-time OMGA stock news. You can receive the latest news about Omega Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About OMGA
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.